Granted Patent
B2
US 12,360,124 · App. 18/668,571 · Granted Jul 15, 2025
Use and treatment of di-amino acid repeat-containing proteins associated with ALS
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
Claims (17)
1. A method of producing an antibody, the method comprising administering to a subject a poly-(Gly-Ala) di-amino acid repeat-containing protein.
2. The method of claim 1 , wherein the poly-(Gly-Ala) di-amino acid repeat-containing protein comprises 2-10,000 di-amino acid repeats.
3. The method of claim 1 , wherein the poly-(Gly-Ala) di-amino acid repeat-containing protein comprises:
(i) the amino acid sequence (GA) x WSGRARGRARGGAAVAVPAPAAAEAQAVASG (SEQ ID NO: 8); or
(ii) the amino acid sequence (AG) x AWSGRARGRARGGAAVAVPAPAAAEAQA VASG (SEQ ID NO: 9),
wherein X represents the number of di-amino acid repeats and is 2-10,000.
4. The method of claim 1 , wherein the poly-(Gly-Ala) di-amino acid repeat-containing protein comprises the sequence set forth in SEQ ID NO: 26.
5. The method of claim 1 , further comprising the step of isolating the antibody.
6. The method of claim 1 , wherein the antibody specifically binds an antigen comprising poly-(Gly-Ala) di-amino acid repeats.
7. The method of claim 1 , wherein the antibody specifically binds an antigen comprising a C-terminal sequence of the poly-(Gly-Ala) di-amino acid repeat-containing protein.
8. The method of claim 1 , wherein the poly-(Gly-Ala) di-amino acid repeating-containing protein comprises 10-200 di-amino acid repeats.
9. The method of claim 1 , wherein the antibody is a polyclonal antibody.
10. The method of claim 1 , wherein the antibody is a monoclonal antibody.
11. The method of claim 1 , wherein the antibody is a humanized antibody.
12. The method of claim 1 , wherein the subject is a mammalian subject.
13. The method of claim 1 , wherein the subject is a mouse.
14. The method of claim 1 , wherein the subject is a rabbit.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 23, 2024
From: RANUM, LAURA; ZU, TAO
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 068383/0764 →
Continuity (7)
Division
14775278
Provisional Application
61883219
· Sep 27, 2013
Provisional Application
61786258
· Mar 14, 2013
References Cited (127)
US 5011912A
· Hopp et al.
· 1991
[cited by applicant]
US 6204008B1
· Borneman
· 2001
[cited by examiner]
US 6342581B1
· Rosen et al.
· 2002
[cited by applicant]
US 7481997B1
· Hardy
· 2009
[cited by applicant]
US 8993633B2
· Megeney et al.
· 2015
[cited by applicant]
US 9448232B2
· Petrucelli et al.
· 2016
[cited by applicant]
US 20020165355A1
· Meheus et al.
· 2002
[cited by applicant]
US 20060068434A1
· Stoerker
· 2006
[cited by applicant]
US 20070004729A1
· Timmer et al.
· 2007
[cited by applicant]
US 20070014810A1
· Baker et al.
· 2007
[cited by applicant]
US 20090074721A1
· Kim et al.
· 2009
[cited by applicant]
US 20090143418A1
· Dixon et al.
· 2009
[cited by applicant]
US 20100298280A1
· Kioschis-Schneider et al.
· 2010
[cited by applicant]
US 20120076785A1
· Nikolaev et al.
· 2012
[cited by applicant]
US 20120094299A1
· Ranum et al.
· 2012
[cited by applicant]
US 20120220534A1
· Levin et al.
· 2012
[cited by applicant]
US 20130115603A9
· Ranum et al.
· 2013
[cited by applicant]
US 20200206255A9
· Ranum et al.
· 2020
[cited by applicant]
US 20200241013A1
· Ranum et al.
· 2020
[cited by applicant]
EP 2837390A1
· 2015
[cited by applicant]
EP 2948471A1
· 2015
[cited by applicant]
EP 3440100A1
· 2019
[cited by applicant]
JP 2019515894A
· 2019
[cited by applicant]
WO WO200175067A2
· 2001
[cited by applicant]
WO WO2006083800A2
· 2006
[cited by applicant]
WO WO2010115033A2
· 2010
[cited by applicant]
WO WO2010132982A1
· 2010
[cited by applicant]
WO WO2013030588A1
· 2013
[cited by applicant]
WO WO2014114303A1
· 2014
[cited by applicant]
WO WO2014114660A1
· 2014
[cited by applicant]
WO WO2014116865A1
· 2014
[cited by applicant]
WO WO2014159247A1
· 2014
[cited by applicant]
WO WO2016025692A1
· 2016
[cited by applicant]
WO WO2017176813A1
· 2017
[cited by applicant]
WO WO2018035408A1
· 2018
[cited by applicant]
WO WO2018195110A1
· 2018
[cited by applicant]
WO WO2019060918A1
· 2019
[cited by applicant]
Extended European Search Report, mailed Sep. 30, 2016, in connection with Application No. EP 14776090.4.
[cited by applicant]
International Search Report and Written Opinion, mailed Aug. 22, 2014, in connection with Application No. PCT/US2014/022670.
[cited by applicant]
International Preliminary Report on Patentability, mailed Sep. 24, 2015, in connection with Application No. PCT/US2014/022670.
[cited by applicant]
International Search Report and Written Opinion, mailed Sep. 21, 2016, in connection with Application No. PCT/US2016/034738.
[cited by applicant]
International Preliminary Report on Patentability, mailed Dec. 14, 2017, in connection with Application No. PCT/US2016/034738.
[cited by applicant]
Supplementary Partial European Search Report, mailed Oct. 18, 2019, in connection with Application No. EP 17779695.0.
[cited by applicant]
Extended European Search Report, mailed Jan. 7, 2020, in connection with Application No. EP 17779695.0.
[cited by applicant]
Extended European Search Report, mailed Dec. 17, 2020, in connection with Application No. EP 18786964.9.
[cited by applicant]
International Preliminary Report on Patentability, mailed Oct. 31, 2019, in connection with Application No. PCT/US2018/028015.
[cited by applicant]
Extended European Search Report, mailed Nov. 26, 2021, in connection with Application No. EP 18860923.4.
[cited by applicant]
International Search Report and Written Opinion, mailed Jan. 15, 2019, in connection with Application No. PCT/US2018/052913.
[cited by applicant]
International Preliminary Report on Patentability, mailed Apr. 9, 2020, in connection with Application No. PCT/US2018/052913.
[cited by applicant]
Extended European Search Report, mailed Jun. 11, 2021, in connection with Application No. EP 18859783.5.
[cited by applicant]
International Search Report and Written Opinion, mailed Dec. 6, 2018, in connection with Application No. PCT/US2018/052745.
[cited by applicant]
International Preliminary Report on Patentability, mailed Apr. 9, 2020, in connection with Application No. PCT/US2018/052745.
[cited by applicant]
Invitation to Pay Additional Fees, mailed Nov. 30, 2020, in connection with Application No. PCT/US2020/051671.
[cited by applicant]
International Search Report and Written Opinion, mailed Feb. 9, 2021, in connection with Application No. PCT/US2020/051671.
[cited by applicant]
International Preliminary Report on Patentability, mailed Mar. 31, 2022, in connection with Application No. PCT/US2020/051671.
[cited by applicant]
International Search Report and Written Opinion, mailed Dec. 31, 2020, in connection with Application No. PCT/US2020/051670.
[cited by applicant]
International Preliminary Report on Patentability, mailed Apr. 7, 2022, in connection with Application No. PCT/US2020/051670.
[cited by applicant]
Invitation to Pay Additional Fees, mailed Feb. 19, 2021, in connection with Application No. PCT/US2020/054976.
[cited by applicant]
International Search Report and Written Opinion, mailed Apr. 23, 2021, in connection with Application No. PCT/US2020/054976.
[cited by applicant]
International Preliminary Report on Patentability, mailed Apr. 21, 2022, in connection with Application No. PCT/US2020/054976.
[cited by applicant]
[No Author Listed] Amersham ECL Western Blotting Detection Reagent. Retrieved from the internet under https://www.cytivalifesciences.com/en/us/shop/protein-analysis/blotting-and-detection/blotting-standards-and-reagents…
[cited by applicant]
[No Author Listed] CRC group Top> L. K. Housing> Query, after sampling and sampling, was conducted, kept still in whole blood ; CRC Corporation, Jun. 30, 2013. https://web.archive.org/web/20130630024235/http://www.crc-g…
[cited by applicant]
[No Author Listed] EBNA1—Epstein-Barr nuclear antigen 1—Epstein-Barr virus (strain GD1) (HHV-4)—EBNA1 gene & protein, Jan. 2018. 2018. Retrieved from the internet under https://www.uniprot.org/uniprot/Q3KSS4 on Sep. 12,…
[cited by applicant]
[No Author Listed], Abstracts. Medizinische Genetik, Berufsverband Nedizinische Genetik, Muchen, DE. Medgen. Mar. 4, 2016; 28(1):84-232. DOI: 10.1007/s11825-016-0083-5.
[cited by applicant]
Ash et al., Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. Feb. 20, 2013;77(4):639-46. doi: 10.1016/j.neuron.2013.02.004. Epub Feb. 12, 2013.
[cited by applicant]
Ashizawa et al., GGCCTG repeats put a hex on Purkinje cells and motor neurons in SCA36. Neurology. Jul. 24, 2012;79(4):302-3. doi: 10.1212/WNL.0b013e31826043d9. Epub Jun. 27, 2012.
[cited by applicant]
Ayhan et al., SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F. EMBO J. Oct. 1, 2018;37(19). pii: e99023. doi: 10.15252/embj.201899023. Epub Sep. 11, 2018.
[cited by applicant]
Baboonian et al., Cross reaction of antibodies to a glycine/alanine repeat sequence of Epstein-Barr virus nuclear antigen-1 with collagen, cytokeratin, and actin. Ann Rheum Dis. Nov. 1991;50(11):772-5.
[cited by applicant]
Bae et al., Antibody-aided clearance of extracellular a-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. Sep. 26, 2012;32(39):13454-69.
[cited by applicant]
Bañez-Coronel et al., A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet. 2012;8(2):e1002481. doi: 10.1371/journal.pgen.1002481. Epub Feb. 23, 2012.
[cited by applicant]
Batra et al., Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum Mol Genet. Apr. 15, 2010;19(R1):R77-82. doi: 10.1093/hmg/ddq132. Epub Apr. 4, 2010.
[cited by applicant]
Carroll et al., Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther. Dec. 2011;19(12):2178-…
[cited by applicant]
Chen et al., Functional genomics in Drosophila models of human disease. Briefings in Functional Genomics. Aug. 22, 2012;11(5):405-415.
[cited by applicant]
Cleary et al., Repeat-associated non-ATG (RAN) translation in neurological disease. Hum Mol Genet. Oct. 15, 2013;22(R1):R45-51. doi: 10.1093/hmg/ddt371. Epub Aug. 4, 2013.
[cited by applicant]
Donnelly et al., RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. Oct. 16, 2013;80(2):415-28. doi: 10.1016/j.neuron.2013.10.015.
[cited by applicant]
Duan et al., Generation of polyclonal antiserum for the detection of methylarginine proteins. J Immunol Methods. Mar. 30, 2007;320(1-2):132-42. Epub Feb. 6, 2007.
[cited by applicant]
Duellman et al., Antigen-binding properties of monoclonal antibodies reactive with EBNA1 and use in immunoaffinity chromatography. PLoS One. 2009;4(2):e4614. doi: 10.1371/journal.pone.0004614. Epub Feb. 26, 2009.
[cited by applicant]
Gkogkas et al., Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. Dec. 11, 2014;9(5):1742-1755. doi: 10.1016/j.celrep.2014.10.064. Epub Nov. 26, 2…
[cited by applicant]
Gómez-Tortosa et al., C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration. Neurology. Jan. 22, 2013;80(4):366-70. doi: 10.1212/WNL.0b013e31827f08ea. Epub Jan. 2, 2013.
[cited by applicant]
Hock et al., Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. May 22, 2003;38(4):547-54.
[cited by applicant]
Jin et al., Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. Neuromolecular Med. Dec. 2016;18(4):581-592. doi: 10.1007/s12017-016-8412-z. Epub…
[cited by applicant]
Kearse et al., CGG Repeat-Associated Non-AUG Translation Utilizes a Cap-Dependent Scanning Mechanism of Initiation to Produce Toxic Proteins. Mol Cell. Apr. 21, 2016;62(2):314-322. doi: 10.1016/j.molcel.2016.02.034. Epu…
[cited by applicant]
Leitman et al., ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. PLoS One. Mar. 3, 2014;9(3):e90803. doi: 10.1371/journal.pone.0090803.
[cited by applicant]
Ma et al., Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett. Jan. 10, 2007;411(2):98-103. doi: 10.1016/j.neulet.2006.10.039. Epub Nov. 15, 2006.
[cited by applicant]
Mirkin, Expandable DNA repeats and human disease. Nature. Jun. 21, 2007;447(7147):932-40. doi: 10.1038/nature05977.
[cited by applicant]
Mori et al., The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. Mar. 15, 2013;339(6125):1335-8. doi: 10.1126/science.1232927. Epub Feb. 7, 2013. Supplementary inform…
[cited by applicant]
Satoh et al., Dystrophic neurites express C9orf72 in Alzheimer's disease brains. Alzheimers Res Ther. Aug. 16, 2012;4(4):33. doi: 10.1186/alzrt136. 13 pages.
[cited by applicant]
Sha et al., Treatment implications of C9ORF72. Alzheimer's Res Ther. Nov. 27, 2012;4(6):46. doi: 10.1186/alzrt149. eCollection 2012.
[cited by applicant]
Shoesmith et al., Amyotrophic lateral sclerosis: update for family physicians. Can Fam Physician. Dec. 2006;52(12):1563-9.
[cited by applicant]
Trouth et al., Myasthenia gravis: a review. Autoimmune Dis.; 2012:874680. doi: 10.1155/2012/874680. Epub Oct. 31, 2012.
[cited by applicant]
Vaughn et al., Inhibition of PKR protects against tunicamycin-induced apoptosis in neuroblastoma cells. Gene. Feb. 15, 2014;536(1):90-6. doi: 10.1016/j.gene.2013.11.074. Epub Dec. 14, 2013.
[cited by applicant]
Wang et al., Comparative Analysis of VOCs in Exhaled Breath of Amyotrophic Lateral Sclerosis and Cervical Spondylotic Myelopathy Patients. Sci Rep. 2016;6:26120. Published May 23, 2016. doi: 10.1038/srep26120.
[cited by applicant]
William et al., Old friends on new paths: metformin as an early phase treatment in Huntington's Disease?, Medizinische Genetik, 28, pp. 215-216, Mar. 4, 2016 (Mar. 4, 2016) (Abstract).
[cited by applicant]
Xiao et al., Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann Neurol. Oct. 2015;78(4):568-83. doi: 10.1002/ana.24469. Epub Aug. 29, 2015.
[cited by applicant]
Yanagisawa et al., Protein Binding of a DRPLA Family Through Arginine-Glutamic Acid Dipeptide repeats is Enhanced by Extended polyglutamine. Human Molecular Genetics. 2000;9(9):1433-1442.
[cited by applicant]
Yu et al., Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. Jul. 2013;10(3):459-72. doi: 10.1007/s13311-013-0187-4.
[cited by applicant]
Zhang et al., Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505-24.
[cited by applicant]
Zhou et al., Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol Med. May 2017;9(5):687-702. doi: 10.15252/emmm.201607054.
[cited by applicant]
Zu et al., RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. Dec. 17, 2013;110(51):E4968-77. doi: 10.1073/pnas.1315438110. Epub Nov. 18, 2013.
[cited by applicant]
Cited By (3)